ClinicalTrials.gg
RecruitingNCT07186842Updated Oct 15, 2026

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

A Phase 1/2 interventional study of BNT329 and CA19-9-targeting monoclonal antibody in Advanced Solid Cancers, sponsored by BioNTech SE. Recruiting at 18 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Primary conditionnone(registry's first term: Bile Duct Neoplasms)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Bile Duct Neoplasms, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by BioNTech SE · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Oct 15, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
245
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are.

The second goal of this study is to evaluate how well BNT329 works. This will be done by measuring the number of participants who respond to the treatment. The length of time where the tumor does not grow or spread will also be measured.

The study will also evaluate how BNT329 moves into, through, and out of the body and how the treatment affects the body.

Read the detailed description

The study will consist of up to four parts (Parts A, B, C, and D).

Parts A and B will be a dose escalation to investigate the safety and tolerability of BNT329. Parts A and B will enroll participants with the following advanced solid tumors known to express carbohydrate antigen 19-9 (CA19-9): pancreatic ductal adenocarcinoma (PDAC) (the most common type of pancreatic cancer), bile duct cancer, a certain type of bladder cancer that started in the lining of the bladder or urinary tract (invasive urothelial carcinoma of the bladder and urinary tract), colorectal cancer, gastroesophageal junction cancer, gastric adenocarcinoma, endometrial cancer, or ovarian cancer. The cancer must not have responded well to previous treatments.

The study will start with recruitment into Part A. Part B (testing a more frequent dosing schedule) will only be opened if indicated by cumulative data from Part A of the study.

Part C (testing pre-dosing with a CA19-9 targeting monoclonal antibody prior to BNT329 administration) will only be opened in case of unforeseen safety and/or weak efficacy signals are detected in Part A and (if opened) Part B. Details on Part C will be added in a future update, if it is necessary, to open this part.

Part D will be a dose optimization and proof-of-concept study to further investigate the safety and tolerability of BNT329 and to investigate preliminary anti-tumor activity. Part D will enroll participants with second-line plus PDAC.

Parts A, B, and C will be non-randomized. In Part D, participants will be randomized (1:1) into one of two arms which will evaluate two dose levels (as selected from Parts A and B).

The study consists of a screening period, a treatment period, an end of treatment visit, two safety follow-up visits, and a survival follow-up period. The treatment period will last for a maximum of 2 years. Participants will remain in the survival follow-up until death, withdrawal of participant's consent, or termination of the study, whichever occurs first.

02

Conditions studied

  • Advanced Solid Cancers

Keywords

  • Anti-drug conjugate (ADC)
  • Bile duct cancer
  • CA19-9
  • Colorectal cancer
  • Endometrial cancer
  • Gastric adenocarcinoma
  • Gastroesophageal junction cancer
  • Invasive urothelial carcinoma of the bladder and urinary tract
  • Ovarian cancer
  • Pancreatic ductal adenocarcinoma
03

In context

Lead sponsor

BioNTech SE is the lead sponsor of 76 studies on the registry; 24 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

All participants and parts:

  • Have an performance score of 0 to 1
  • Have per v1.1, except for ovarian cancer where participants will be evaluated according to Gynecologic Cancer InterGroup criteria.
  • Have a of ≥3 months in the opinion of the investigator.
  • Have adequate organ, coagulation, and hematologic function as defined in the protocol.

Parts A, B, and C:

  • Have a confirmed advanced/ tumor type that is known to express CA19-9: PDAC, carcinoma of the bile ducts, invasive urothelial carcinoma of the bladder and urinary tract, colorectal adenocarcinoma, adenocarcinoma of the esophagogastric junction, gastric adenocarcinoma, endometrial carcinoma, and epithelial ovarian cancer (including adenocarcinoma of the fallopian tube and peritoneal epithelial cancer [except mesothelioma]).
  • Have no available standard of care therapy likely to confer clinical benefit in the opinion of the investigator. Participants must have received all available standard therapies, including targeted therapies based on mutation status (per guidelines from the Food and Drug Administration, American Society of Clinical Oncology, European Society for Medical Oncology, or local guidelines used at the site), and failed at least standard of care therapy prior to enrollment.

Part D:

  • Have a histologically confirmed diagnosis of PDAC.
  • Must have been offered all available standard therapies including targeted therapies based on mutation status. Established second-line therapies available must not be withheld.
  • Have radiographic disease progression and no available standard of care therapy likely to confer clinical benefit in the opinion of the investigator.

Key Exclusion Criteria

All participants and parts:

  • Are enrolled in another study or are subject to exclusion periods from another investigational study.
  • Have had an inadequate for prior anticancer treatment prior to the first dose of investigational medicinal product (IMP) as defined in the protocol.
  • Have received systemic (>10 mg/day of prednisone or its equivalent) or other therapy within 2 weeks prior to the first dose of IMP. The following are exceptions to this criterion:

    • Inhaled sprays, topical steroids, or local steroid injections (e.g., intra-articular injection).
    • Systemic steroids at physiological doses as replacement therapy (e.g., physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency).
    • Steroids as pre-medication for reactions (e.g., computed tomography (CT) scan pre-medication).
  • Have received any within 4 weeks prior to the first dose of IMP or intend to receive a live vaccine during the study.
  • Have or spinal cord compression unless asymptomatic or treated and stable off steroids and anticonvulsants for at least 2 weeks prior to the first dose of IMP.
  • Have a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • Have active gastric and duodenal ulcers, ulcerative colitis, or other gastrointestinal conditions that may cause bleeding or perforation in the opinion of the treating investigator.
  • Have an active infection that requires systemic therapy within 1 week prior to the first dose of IMP. Participants receiving prophylactic anti-infective therapy (e.g., to prevent a urinary tract infection or exacerbation) may be eligible after discussion with the sponsor.
  • Have unresolved toxicities from previous anticancer therapy as defined in the protocol.

NOTE: Other protocol defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
245 participants (estimated)

Study arms

  • Experimental
    Dose Escalation - Part A

    BNT329 administered once every 3 weeks at protocol-defined dose levels

    Drug: BNT329

  • Experimental
    Dose Escalation - Part B

    BNT329 administered once every 2 weeks at protocol-defined dose levels

    Drug: BNT329

  • Experimental
    Dose Escalation: Part C

    BNT329 administered after pre-dosing with a CA19-9 targeting monoclonal antibody

    Drug: BNT329 · Drug: CA19-9-targeting monoclonal antibody

  • Experimental
    Dose Expansion - Part D

    Participants will be randomized to one of two arms evaluating two different doses as selected from Parts A, B, and/or C

    Drug: BNT329

Interventions

  • DrugBNT329

    Intravenous (IV) infusion

  • DrugCA19-9-targeting monoclonal antibody

    Monoclonal antibody

06

What researchers measure

Primary outcomes

  1. Parts A and B - Occurrence of dose-limiting toxicities within a participant

    Per dose level.

    Time frame: First 21 days (Part A) or 28 days (Part B) after the first dose of BNT329.

  2. Parts A, B, and D - Occurrence of treatment-emergent adverse events (TEAEs), Grade ≥3 TEAEs, serious adverse events (SAEs), treatment-related TEAEs, treatment-related Grade ≥3 TEAEs, and treatment-related SAEs

    Per dose level.

    Time frame: From first dose of BNT329 until 60 days after the last dose of BNT329 (up to 26 months).

  3. Parts A, B, and D - Occurrence of dose interruptions, reductions, and discontinuation of BNT329 due to TEAEs

    Per dose level.

    Time frame: From the time of initiation of the first dose of BNT329 until 60 days after the last dose of BNT329 (up to 26 months).

  4. Part D - Objective response rate (ORR)

    Per dose level. Defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) (based on the investigator's assessment) is observed as best overall response.

    Time frame: From first dose of BNT329 until end of study (up to approximately 36 months).

Secondary outcomes

  1. Parts A, B, and D - Assessment of area under the curve derived from serum/plasma concentrations of CA19-9-unbound ADC, CA19-9-unbound total anti-CA19-9 antibody, and unconjugated YL0010014 payload

    Per dose level (if data permit)

    Time frame: First 21 days (Part A) or 28 days (Part B) after the first dose of BNT329.

  2. Parts A, B, and D - Assessment of maximum concentration derived from serum/plasma concentrations of CA19-9-unbound ADC, CA19-9-unbound total anti-CA19-9 antibody, and unconjugated YL0010014 payload

    Per dose level (if data permit).

    Time frame: First 21 days (Part A) or 28 days (Part B) after the first dose of BNT329.

  3. Parts A, B, and D - Assessment of time to reach maximum concentration derived from serum/plasma concentrations of CA19-9-unbound ADC, CA19-9-unbound total anti-CA19-9 antibody, and unconjugated YL0010014 payload

    Per dose level (if data permit).

    Time frame: First 21 days (Part A) or 28 days (Part B) after the first dose of BNT329.

  4. Parts A, B, and D - Assessment of terminal half-life derived from serum/plasma concentrations of CA19-9-unbound ADC, CA19-9-unbound total anti-CA19-9 antibody, and unconjugated YL0010014 payload

    Per dose level (if data permit).

    Time frame: First 21 days (Part A) or 28 days (Part B) after the first dose of BNT329.

  5. Parts A and B - ORR

    Per dose level. Defined as the proportion of participants in whom a confirmed CR or PR (based on the investigator's assessment) is observed as best overall response.

    Time frame: From first dose of BNT329 until end of study (up to approximately 36 months).

  6. Parts A, B, and D - Disease control rate

    Per dose level. Defined as the proportion of participants in whom a CR or PR or stable disease (assessed at least 6 weeks \[±2 days\] after the first BNT329 dose) is observed as best overall response per investigator's assessment.

    Time frame: From first dose of BNT329 until end of study (up to approximately 36 months).

  7. Parts A, B, and D - Duration of response

    Per dose level. Defined as the time from first objective response (CR or PR) to first occurrence of objective tumor progression (PD) or death from any cause, whichever occurs first.

    Time frame: From first dose of BNT329 until end of study (up to approximately 36 months).

  8. Parts A, B, and D - Progression free survival

    Per dose level. Defined as the time from first dose of BNT329 to first objective tumor progression (PD per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\] based on the investigator's assessment), or death from any cause, whichever occurs first.

    Time frame: From first dose of BNT329 until end of study (up to approximately 36 months).

  9. Part D - Overall survival

    Per dose level. Defined as the time from first dose of BNT329 to death from any cause.

    Time frame: From first dose of BNT329 until end of study (up to approximately 36 months).

  10. Parts A, B, and D: Anti-drug antibody (ADA) prevalence

    Per dose level/cohort. Defined as the proportion of participants who are ADA positive at any timepoint (either baseline or post-baseline) (if data permit).

    Time frame: From first dose of BNT329 until up to 60 days after the last dose of BNT329 (up to 26 months).

  11. Parts A, B, and D - ADA incidence

    Per dose level/cohort. Defined as the proportion of participants having treatment-emergent ADA (if data permit).

    Time frame: From first dose of BNT329 until up to 60 days after the last dose of BNT329 (up to 26 months).

07

Study locations

18 of 18 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for May 2030, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Sep 22, 2025
StartActual
Nov 18, 2025
Primary completionEst.
May 2030
CompletionEst.
May 2030
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Karmanos Cancer Institute · Detroit, United States
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    1 site added
    Show site
    • Karmanos Cancer Institute · Detroit, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07186842
Lead sponsor
BioNTech SE
Responsible party
Sponsor
First posted
Sep 22, 2025
Start date
Nov 18, 2025
Primary completion
May 2030 (estimated)
Completion
May 2030 (estimated)
Last update
Oct 15, 2026

Study contacts

BioNTech clinical trials patient information
Contact
patients@biontech.de
+49 6131 9084 ext. 0
BioNTech Response Person
study director · BioNTech SE

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion